Nickan Research Institute Journal of Renal Endocrinology 2423-6438 11 1 2025 01 01 Febuxostat versus allopurinol for renoprotection; a mini-review on recent concepts e25184 e25184 10.34172/jre.2025.25184 EN Hossein Mardanparvar https://orcid.org/0000-0001-7455-5373 Journal Article 10.34172/jre.2025.25184 2024 11 13 2025 02 06 Both febuxostat and allopurinol inhibit xanthine oxidase to reduce uric acid levels, febuxostat is more selective and potent in its mechanism of action, does not require dose adjustments based on kidney function, and does not affect other enzymes involved in nucleic acid synthesis.